Stable pharmaceutical formulations comprising lubiprostone
OwnerBernard Charles Shermaninventor
Life of this patent
Estimating the term…
Abstract
Provided is a pharmaceutical formulation comprising lubiprostone and at least one propylene glycol ester. The propylene glycol ester is typically selected from the group consisting of: propylene glycol mono-ester of lauric acid, propylene glycol mono-ester of caprylic acid, propylene glycol mono-ester of capric acid, propylene glycol di-ester of lauric acid, propylene glycol di-ester of caprylic acid and propylene glycol di-ester of capric acid.
Claims7
A pharmaceutical formulation comprising lubiprostone and a propylene glycol ester, wherein the propylene glycol ester is a mixture of propylene glycol di-ester of caprylic acid and propylene glycol di-ester of capric acid, and the mixture has a di-ester content greater than its mono-ester content.
Dependencies are inferred from the claim text.